GOSSAMER BIO, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
GOSSAMER BIO, INC. (GOSS) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $2.46 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-13
- GOSSAMER BIO, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $2.46M, a 4.76% decline year-over-year.
- GOSSAMER BIO, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $6.30M, a 162.12% increase year-over-year.
- GOSSAMER BIO, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $2.67M, a 44.94% decline year-over-year.
- GOSSAMER BIO, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $2.59M, a 48.29% decline year-over-year.
- GOSSAMER BIO, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $10.55M, a 48.81% decline from fiscal 2024.
- GOSSAMER BIO, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $20.62M, a 27.70% decline from fiscal 2023.
- GOSSAMER BIO, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $28.52M, a 32.98% decline from fiscal 2022.
- GOSSAMER BIO, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $42.55M, a 32.94% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.46M 10-Q · filed 2026-08-13 | $8.77M derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2026-03-31 | $6.30M 10-Q · filed 2026-08-13 | |||
| 2025-12-31 | $10.55M 10-K · filed 2026-03-17 | |||
| 2025-09-30 | $2.67M 10-Q · filed 2025-11-05 | $5.25M derived: sum of 2 quarters · filed 2026-08-13 | $7.66M derived: sum of 3 quarters · filed 2026-08-13 | |
| 2025-06-30 | $2.59M 10-Q · filed 2026-08-13 | $4.99M derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2025-03-31 | $2.40M 10-Q · filed 2026-08-13 | |||
| 2024-12-31 | $20.62M 10-K · filed 2026-03-17 | |||
| 2024-09-30 | $4.84M 10-Q · filed 2025-11-05 | $9.84M derived: sum of 2 quarters · filed 2025-11-05 | $15.65M derived: sum of 3 quarters · filed 2025-11-05 | |
| 2024-06-30 | $5.00M 10-Q · filed 2025-11-05 | $10.81M derived: sum of 2 quarters · filed 2025-11-05 | ||
| 2024-03-31 | $5.81M 10-Q · filed 2025-11-05 | |||
| 2023-12-31 | $28.52M 10-K · filed 2026-03-17 | |||
| 2023-09-30 | $6.16M 10-Q · filed 2024-11-07 | $14.36M derived: sum of 2 quarters · filed 2024-11-07 | $22.49M derived: sum of 3 quarters · filed 2024-11-07 | |
| 2023-06-30 | $8.20M 10-Q · filed 2024-11-07 | $16.32M derived: sum of 2 quarters · filed 2024-11-07 | ||
| 2023-03-31 | $8.13M 10-Q · filed 2024-11-07 | |||
| 2022-12-31 | $42.55M 10-K · filed 2025-03-13 | |||
| 2022-09-30 | $10.12M 10-Q · filed 2023-11-09 | $20.12M derived: sum of 2 quarters · filed 2023-11-09 | $31.10M derived: sum of 3 quarters · filed 2023-11-09 | |
| 2022-06-30 | $10.00M 10-Q · filed 2023-11-09 | $20.98M derived: sum of 2 quarters · filed 2023-11-09 | ||
| 2022-03-31 | $10.98M 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | $32.01M 10-K · filed 2024-03-05 | |||
| 2021-09-30 | $7.59M 10-Q · filed 2022-11-03 | $15.64M derived: sum of 2 quarters · filed 2022-11-03 | $24.35M derived: sum of 3 quarters · filed 2022-11-03 | |
| 2021-06-30 | $8.05M 10-Q · filed 2022-11-03 | $16.76M derived: sum of 2 quarters · filed 2022-11-03 | ||
| 2021-03-31 | $8.71M 10-Q · filed 2022-11-03 | |||
| 2020-12-31 | $38.75M 10-K · filed 2023-03-17 | |||
| 2020-09-30 | $8.92M 10-Q · filed 2021-11-08 | $17.82M derived: sum of 2 quarters · filed 2021-11-08 | $26.07M derived: sum of 3 quarters · filed 2021-11-08 | |
| 2020-06-30 | $8.90M 10-Q · filed 2021-11-08 | $17.14M derived: sum of 2 quarters · filed 2021-11-08 | ||
| 2020-03-31 | $8.24M 10-Q · filed 2021-11-08 | |||
| 2019-12-31 | $20.82M 10-K · filed 2022-03-03 | |||
| 2019-09-30 | $5.73M 10-Q · filed 2020-11-10 | $10.87M derived: sum of 2 quarters · filed 2020-11-10 | $13.96M derived: sum of 3 quarters · filed 2020-11-10 | |
| 2019-06-30 | $5.14M 10-Q · filed 2020-11-10 | $8.23M derived: sum of 2 quarters · filed 2020-11-10 | ||
| 2019-03-31 | $3.09M 10-Q · filed 2020-11-10 | |||
| 2018-12-31 | $30.95M 10-K · filed 2021-02-26 | |||
| 2018-09-30 | $18.17M 10-Q · filed 2019-11-12 | $19.54M derived: sum of 2 quarters · filed 2019-11-12 | $20.15M derived: sum of 3 quarters · filed 2019-11-12 | |
| 2018-06-30 | $1.37M 10-Q · filed 2019-11-12 | $1.98M derived: sum of 2 quarters · filed 2019-11-12 | ||
| 2018-03-31 | $605.00K 10-Q · filed 2019-11-12 | |||
| 2017-12-31 | $32.00K 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 |